Received substantial research grants during the year from the German government for continued studies of a proprietary vena cava filter technology.
Worked closely with Biophan Technologies on the execution of milestone, multimillion dollar licensing and equity agreements with Boston Scientific.

In response to the 2005 accomplishments, Michael Weiner, CEO of Biophan Technologies, said, "Our acquisition in May of what would become Biophan Europe was without doubt one of the past year's most important achievements. Biophan Europe's research has generated 15 additions to Biophans extensive intellectual property portfolio, further strengthening our MRI technology leadership. The acquisition also brought new world-class scientific personnel and additional access to the European research community, where some of the most exciting research into MRI is being conducted. We are delighted with the past years progress and look forward to additional advancements in 2006, both at Biophan Europe and at Biophan Technologies."


About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems which derive energy from body heat. Biophan also has an equity position in MYOTECH, LLC to assist in development and commercialization of an MRI compatible cardiac assist device - the MYO-VAD(TM). Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications, plus international applications. This total includes 45 issued U.S. patents, 7 recently-allowed applications that will issue as patents in the near future, and 104 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials which generate electricity from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol BTN.
For more information, please visit www.biophan.com.

Back to HCB News

More Voices